FTC Weight-Loss Advertising Rules: What GLP-1 Clinics Can’t Claim

The FTC has been unusually active on weight-loss advertising over the past several years, and GLP-1 telehealth clinics sit squarely in its crosshairs. A claim that reads as reasonable marketing copy can double as exactly the kind of unsubstantiated health claim the FTC's enforcement actions have specifically targeted.

The FTC's Health Products Compliance Framework, Applied to Weight Loss

The FTC requires that any health-related claim be backed by competent and reliable scientific evidence before it's made, not after. For weight-loss specifically, the FTC's long-standing guidance flags phrases implying dramatic or effortless results, "lose 30 pounds without diet or exercise," as the kind of claim that draws enforcement attention regardless of how the underlying medication actually performs in trials.

What Counts as an Unsubstantiated Result Claim

Specific weight-loss numbers ("lose up to 20% of body weight"), timeline promises ("see results in two weeks"), and comparisons implying superiority over other treatments without head-to-head data all fall into this category. Clinical trial data can generally be referenced, but it needs accurate framing: which population was studied, over what timeframe, and with what other interventions alongside the medication.

Compounded GLP-1 Products Face Extra Scrutiny

Marketing for compounded semaglutide or tirzepatide carries additional risk beyond standard weight-loss claims, since compounded versions aren't FDA-approved in the same way brand-name products are, and the regulatory status of compounding pharmacies producing these drugs has shifted as the FDA's shortage declarations have changed. Claims implying FDA approval or equivalence to the branded product need particular care given how actively this specific area is being watched.

Building Substantiation Into the Content Process

The clinics that stay out of trouble treat every result claim as needing a citation before it publishes, not a citation added if someone asks later. That means clinical or prescribing staff reviewing marketing copy before it goes live, not marketing writing first and medical review catching problems after the fact.

Tridigiam builds weight-loss and telehealth marketing content with this review process in mind by default, but we're not a medical or legal compliance firm, and specific claims need sign-off from your clinical and compliance team before they publish. For the broader picture on telehealth marketing, see our Telehealth & GLP-1 Marketing guide.

Frequently asked questions

Can a telehealth clinic advertise a specific amount of weight loss?

Only with substantiation from competent, reliable scientific evidence behind the specific figure, and accurate framing of the population and conditions that evidence reflects. Generic or exaggerated figures are exactly what FTC enforcement has targeted.

Is compounded semaglutide marketing riskier than branded GLP-1 marketing?

Generally yes, given the regulatory status of compounded products has been actively shifting, and claims implying FDA approval or brand equivalence carry meaningful additional risk.

Do before-and-after weight-loss photos need special handling?

Yes. They need documented patient consent and should avoid implying a typical or guaranteed result, similar to the before-and-after standard in other medical marketing categories.

What's the biggest mistake weight-loss clinics make with marketing?

Writing a compelling result claim first and checking for substantiation after, instead of starting from what can actually be supported and building the copy around that.